Nuvation Bio (NYSE:NUVB) Stock Price Up 3.9%

Nuvation Bio Inc. (NYSE:NUVB - Get Free Report)'s share price traded up 3.9% during trading on Thursday . The company traded as high as $3.17 and last traded at $3.17. 174,027 shares were traded during mid-day trading, a decline of 85% from the average session volume of 1,197,210 shares. The stock had previously closed at $3.05.

Analyst Ratings Changes

Several equities analysts have recently issued reports on NUVB shares. Jefferies Financial Group upgraded shares of Nuvation Bio from a "hold" rating to a "buy" rating and upped their price objective for the company from $1.40 to $10.00 in a report on Wednesday, March 27th. Wedbush restated an "outperform" rating and set a $5.00 price objective on shares of Nuvation Bio in a report on Friday, March 1st. BTIG Research upgraded shares of Nuvation Bio from a "neutral" rating to a "buy" rating and set a $5.00 price objective on the stock in a report on Tuesday, March 26th. Finally, HC Wainwright upped their price objective on shares of Nuvation Bio from $5.00 to $8.00 and gave the company a "buy" rating in a report on Thursday, March 28th.

Nuvation Bio Trading Up 3.1 %

The company has a 50-day simple moving average of $2.33 and a 200 day simple moving average of $1.70. The firm has a market cap of $685.77 million, a PE ratio of -9.38 and a beta of 1.37.

Nuvation Bio (NYSE:NUVB - Get Free Report) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04. On average, equities analysts expect that Nuvation Bio Inc. will post -0.35 earnings per share for the current year.

Institutional Investors Weigh In On Nuvation Bio

Hedge funds have recently bought and sold shares of the stock. Clarius Group LLC acquired a new position in shares of Nuvation Bio during the 3rd quarter worth approximately $26,000. Centiva Capital LP acquired a new position in shares of Nuvation Bio during the 4th quarter worth approximately $26,000. Royal Bank of Canada raised its stake in shares of Nuvation Bio by 133.4% during the 2nd quarter. Royal Bank of Canada now owns 15,199 shares of the company's stock worth $27,000 after buying an additional 8,687 shares during the period. Virtu Financial LLC acquired a new position in shares of Nuvation Bio during the 4th quarter worth approximately $31,000. Finally, Beacon Pointe Advisors LLC acquired a new position in shares of Nuvation Bio during the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own 61.67% of the company's stock.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.